Janux Therapeutics (NASDAQ:JANX) Trading Down 4.1%

Janux Therapeutics, Inc. (NASDAQ:JANX)’s share price was down 4.1% during mid-day trading on Wednesday . The company traded as low as $48.00 and last traded at $48.46. Approximately 288,929 shares were traded during trading, a decline of 62% from the average daily volume of 755,735 shares. The stock had previously closed at $50.55.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the company. Wedbush reissued an “outperform” rating and set a $53.00 price target on shares of Janux Therapeutics in a research report on Monday, March 11th. Bank of America upped their price target on Janux Therapeutics from $24.00 to $48.00 and gave the stock a “buy” rating in a research note on Wednesday, March 13th. Cantor Fitzgerald started coverage on Janux Therapeutics in a research note on Wednesday, March 20th. They set an “overweight” rating and a $100.00 price target for the company. William Blair restated an “outperform” rating on shares of Janux Therapeutics in a research note on Tuesday, February 27th. Finally, Jonestrading assumed coverage on Janux Therapeutics in a research note on Tuesday. They set a “buy” rating and a $70.00 target price for the company. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Janux Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $61.33.

Janux Therapeutics Stock Down 0.3 %

The stock has a fifty day moving average price of $34.41 and a 200-day moving average price of $17.82.

Janux Therapeutics (NASDAQ:JANX) last issued its earnings results on Friday, March 8th. The company reported ($0.25) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.12. Janux Therapeutics had a negative return on equity of 17.88% and a negative net margin of 721.18%. The business had revenue of $2.46 million during the quarter, compared to analysts’ expectations of $0.98 million. Research analysts predict that Janux Therapeutics, Inc. will post -1.41 earnings per share for the current year.

Hedge Funds Weigh In On Janux Therapeutics

A number of hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. raised its holdings in shares of Janux Therapeutics by 3.9% in the 4th quarter. Vanguard Group Inc. now owns 979,483 shares of the company’s stock worth $10,510,000 after buying an additional 37,202 shares in the last quarter. Goldman Sachs Group Inc. increased its holdings in Janux Therapeutics by 174.7% during the 4th quarter. Goldman Sachs Group Inc. now owns 39,948 shares of the company’s stock valued at $429,000 after purchasing an additional 25,404 shares in the last quarter. Barclays PLC increased its holdings in Janux Therapeutics by 166.3% during the 4th quarter. Barclays PLC now owns 47,722 shares of the company’s stock valued at $511,000 after purchasing an additional 29,800 shares in the last quarter. Nuveen Asset Management LLC increased its holdings in Janux Therapeutics by 22.3% during the 4th quarter. Nuveen Asset Management LLC now owns 81,574 shares of the company’s stock valued at $875,000 after purchasing an additional 14,872 shares in the last quarter. Finally, Northern Trust Corp increased its holdings in Janux Therapeutics by 5.9% during the 4th quarter. Northern Trust Corp now owns 204,002 shares of the company’s stock valued at $2,189,000 after purchasing an additional 11,317 shares in the last quarter. 75.39% of the stock is owned by institutional investors and hedge funds.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.